News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,882 Results
Type
Article (1147)
Press Release (20735)
Section
Business (11211)
Career Advice (24)
Deals (1477)
Drug Development (2175)
FDA (318)
Job Trends (563)
News (14090)
Policy (605)
Tag
Academia (12)
Allergies (3)
Alliances (786)
ALS (3)
Alzheimer's disease (14)
Antibody-drug conjugate (ADC) (12)
Approvals (343)
Artificial intelligence (3)
Autoimmune disease (1)
Bankruptcy (7)
Best Places to Work (494)
Biosimilars (4)
Bladder cancer (17)
Breast cancer (19)
Cancer (141)
Cardiovascular disease (19)
Career advice (22)
CAR-T (1)
Cell therapy (4)
Cervical cancer (2)
Clinical research (1949)
Collaboration (9)
Compensation (13)
COVID-19 (27)
C-suite (1)
Data (189)
Depression (2)
Diabetes (19)
Diagnostics (211)
Digital health (2)
Drug discovery (5)
Duchenne muscular dystrophy (1)
Earnings (10616)
Editorial (1)
Events (1933)
Executive appointments (4)
FDA (488)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (14)
Gene editing (1)
Generative AI (1)
Gene therapy (10)
GLP-1 (34)
Government (60)
Guidances (113)
Healthcare (485)
HIV (7)
IgA nephropathy (1)
Immunology and inflammation (5)
Indications (9)
Infectious disease (39)
Inflammatory bowel disease (6)
Influenza (1)
Intellectual property (4)
Interviews (3)
IPO (1091)
Job creations (129)
Job search strategy (22)
Kidney cancer (1)
Labor market (1)
Layoffs (5)
Legal (97)
Lung cancer (26)
Lymphoma (18)
Manufacturing (8)
MASH (8)
Medical device (590)
Medtech (593)
Mergers & acquisitions (391)
Metabolic disorders (47)
Multiple sclerosis (5)
NASH (2)
Neurodegenerative disease (3)
Neuropsychiatric disorders (2)
Neuroscience (38)
NextGen: Class of 2026 (148)
Non-profit (23)
Now hiring (2)
Obesity (21)
Opinion (3)
Ovarian cancer (12)
Pancreatic cancer (3)
Parkinson's disease (4)
Patents (5)
Patient recruitment (2)
Peanut (1)
People (715)
Pharmacy benefit managers (1)
Phase 1 (490)
Phase 2 (841)
Phase 3 (881)
Pipeline (489)
Policy (2)
Postmarket research (62)
Preclinical (130)
Prostate cancer (3)
Radiopharmaceuticals (4)
Rare diseases (18)
Real estate (118)
Regulatory (521)
Research institute (17)
Resumes & cover letters (4)
Rett syndrome (7)
RSV (8)
Schizophrenia (2)
Sickle cell disease (3)
Special edition (1)
Sponsored (1)
Startups (69)
Supply chain (1)
Tariffs (2)
Vaccines (20)
Weight loss (17)
Women's health (3)
Date
Last 7 days (17)
Last 30 days (66)
Last 365 days (1188)
2026 (87)
2025 (1206)
2024 (1350)
2023 (1489)
2022 (1589)
2021 (1590)
2020 (1370)
2019 (892)
2018 (755)
2017 (510)
2016 (325)
2015 (7162)
2014 (347)
2013 (209)
2012 (287)
2011 (361)
2010 (315)
Location
Africa (28)
Alabama (4)
Arizona (4)
Asia (1268)
Australia (153)
California (397)
Canada (101)
China (21)
Colorado (17)
Connecticut (13)
Delaware (20)
Europe (3158)
Florida (45)
Georgia (17)
Illinois (33)
India (1)
Indiana (26)
Japan (15)
Kentucky (3)
Louisiana (6)
Maine (10)
Maryland (55)
Massachusetts (259)
Michigan (17)
Minnesota (20)
Missouri (1)
Montana (3)
Nevada (2)
New Hampshire (5)
New Jersey (285)
New York (117)
North Carolina (57)
Northern California (193)
Ohio (11)
Pennsylvania (104)
South America (40)
Southern California (181)
Tennessee (2)
Texas (43)
United States (1596)
Utah (21)
Virginia (7)
Washington D.C. (1)
Washington State (26)
Wisconsin (7)
21,882 Results for "157".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
October 27, 2025
·
8 min read
Biotech Beach
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Engrail Therapeutics today announced the close of an oversubscribed $157 million Series B financing round.
March 19, 2024
·
2 min read
Genomics Market Size To Hit USD 157.47 Billion By 2033
The global genomics market size was valued at USD 33.90 billion in 2023 and is poised to grow from USD 39.53 billion in 2024 to USD 157.47 billion by 2033, growing at a CAGR of 16.6% in the forecast period (2024-2033).
April 9, 2024
·
15 min read
Press Releases
SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity
November 15, 2024
·
2 min read
Press Releases
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034
November 14, 2024
·
1 min read
Press Releases
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
October 25, 2024
·
3 min read
Drug Development
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward
Engrail Therapeutics’ latest financing round will give it enough funds to advance its candidates for neuropsychiatric and neurodevelopmental disorders through clinical development.
March 19, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Pharmaceutical Filtration Market to Surge from USD 1.57 Bn to USD 14.45 Bn by 2033: A Comprehensive Growth Analysis
July 30, 2024
·
16 min read
Weight loss
Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout
The latest data showed 15.7% weight loss in patients with diabetes after 68 weeks. In December 2024, CagriSema returned another disappointing readout for Novo, eliciting weight-loss of 22.7% in patients without diabetes, below the pharma’s prior projection of 25%.
March 10, 2025
·
2 min read
·
Tristan Manalac
Biotech Beach
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.
December 12, 2022
·
8 min read
1 of 2,189
Next
